OS Therapies (OSTX) Competitors $2.19 +0.07 (+3.11%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OSTX vs. ALEC, ACB, NGNE, DBVT, RAPT, ANNX, CADL, NMRA, RNAC, and JBIOShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Alector (ALEC), Aurora Cannabis (ACB), Neurogene (NGNE), DBV Technologies (DBVT), Rapt Therapeutics (RAPT), Annexon (ANNX), Candel Therapeutics (CADL), Neumora Therapeutics (NMRA), Cartesian Therapeutics (RNAC), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Its Competitors Alector Aurora Cannabis Neurogene DBV Technologies Rapt Therapeutics Annexon Candel Therapeutics Neumora Therapeutics Cartesian Therapeutics Jade Biosciences Alector (NASDAQ:ALEC) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings. Do institutionals and insiders hold more shares of ALEC or OSTX? 85.8% of Alector shares are owned by institutional investors. 9.7% of Alector shares are owned by insiders. Comparatively, 10.3% of OS Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer ALEC or OSTX? In the previous week, Alector had 2 more articles in the media than OS Therapies. MarketBeat recorded 3 mentions for Alector and 1 mentions for OS Therapies. Alector's average media sentiment score of 0.72 beat OS Therapies' score of 0.44 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OS Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ALEC or OSTX more profitable? OS Therapies has a net margin of 0.00% compared to Alector's net margin of -142.10%. OS Therapies' return on equity of 0.00% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-142.10% -112.06% -26.37% OS Therapies N/A N/A -569.57% Which has higher earnings and valuation, ALEC or OSTX? OS Therapies has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than OS Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$81.13M4.04-$119.05M-$1.16-2.79OS TherapiesN/AN/A-$7.79M-$0.79-2.77 Do analysts prefer ALEC or OSTX? Alector presently has a consensus target price of $4.17, suggesting a potential upside of 28.80%. OS Therapies has a consensus target price of $18.00, suggesting a potential upside of 723.42%. Given OS Therapies' stronger consensus rating and higher probable upside, analysts plainly believe OS Therapies is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOS Therapies beats Alector on 8 of the 14 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$69.18M$853.50M$5.81B$21.58BDividend YieldN/A4.84%5.61%3.51%P/E Ratio-2.771.18350.7630.17Price / SalesN/A25.94520.1477.25Price / CashN/A17.6526.0118.30Price / BookN/A6.4915.484.64Net Income-$7.79M-$3.95M$3.30B$1.00B7 Day Performance-0.64%-0.01%200.54%0.78%1 Month Performance-11.85%6.00%184.07%2.71%1 Year Performance-37.18%21.14%325.10%14.68% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.0809 of 5 stars$2.19+3.1%$18.00+723.4%-39.1%$69.18MN/A-2.77N/AGap UpALECAlector3.7837 of 5 stars$2.96+7.6%$4.17+40.8%-47.3%$278.33M$100.56M-2.55270ACBAurora Cannabis0.5074 of 5 stars$4.97+2.1%N/A-11.0%$274.93M$357.88M-26.161,130NGNENeurogene1.429 of 5 stars$17.45-8.2%$46.17+164.6%-57.8%$271.17M$930K-4.0590Positive NewsDBVTDBV Technologies2.865 of 5 stars$9.90+0.3%$14.75+49.0%+155.0%$270.39M$4.15M-2.0880High Trading VolumeRAPTRapt Therapeutics3.9175 of 5 stars$17.42+7.4%$21.57+23.8%+38.7%$268.24M$1.53M-1.2380Positive NewsGap DownANNXAnnexon1.5098 of 5 stars$2.49+2.9%$12.50+402.0%-59.3%$265.93MN/A-1.9360CADLCandel Therapeutics2.554 of 5 stars$4.85+1.3%$20.00+312.4%-36.2%$262.95M$120K-7.0360Positive NewsAnalyst UpgradeNMRANeumora Therapeutics2.5459 of 5 stars$1.52-6.2%$7.14+369.9%-86.4%$262.35MN/A-0.97108High Trading VolumeRNACCartesian Therapeutics1.5851 of 5 stars$9.79+1.1%$40.00+308.6%-41.1%$251.70M$1.03M-0.1964Gap UpJBIOJade Biosciences1.7012 of 5 stars$7.07-8.2%$16.00+126.3%N/A$251.23MN/A-0.2320Positive News Related Companies and Tools Related Companies Alector Competitors Aurora Cannabis Competitors Neurogene Competitors DBV Technologies Competitors Rapt Therapeutics Competitors Annexon Competitors Candel Therapeutics Competitors Neumora Therapeutics Competitors Cartesian Therapeutics Competitors Jade Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OSTX Stock Alerts